Jan. 26 at 3:17 PM
$ADMA Doing a little historical analysis this morning. Doesn't mean we will see a repeat, but it is interesting nonetheless.
Overall pattern: In each of the past 3 cycles, ADMA's share price has shown consistent positive performance from the Q3 earnings release to the Q4/full-year release. This period (roughly Nov to Feb/Mar) has captured seasonal strength, operational improvements (e.g., revenue ramps from products like Asceniv/Bivigam), profitability turnaround, and positive market sentiment toward the biotech's growth story. Gains ranged from strong double-digit percentages to multiples in earlier years, though more moderated in recent cycles as the base price increased.
